{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T13:28:53Z","timestamp":1649683733079},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T00:00:00Z","timestamp":1583366400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T00:00:00Z","timestamp":1583366400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s00059-020-04896-1","type":"journal-article","created":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T14:04:03Z","timestamp":1583417043000},"page":"201-208","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Grundlagen der Angiologie bei peripherer arterieller Verschlusskrankheit (pAVK)"],"prefix":"10.1007","volume":"45","author":[{"given":"Christine","family":"Espinola-Klein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,5]]},"reference":[{"key":"4896_CR1","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","volume":"39","author":"V Aboyans","year":"2017","unstructured":"Aboyans\u00a0V, Ricco\u00a0JB, Bartelink\u00a0MEL et\u00a0al (2017) ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Eur Heart\u00a0J 39:763\u2013816","journal-title":"Eur Heart J"},{"issue":"Suppl 95","key":"4896_CR2","first-page":"11","volume":"45","author":"H Lawall","year":"2016","unstructured":"Lawall\u00a0H, Huppert\u00a0P, R\u00fcmenapf\u00a0G et al (2016) S3-Leitlinien zur Diagnostik, Therapie und Nachsorge der peripheren arteriellen Verschlusskrankheit. Vasa 45(Suppl 95):11\u201382","journal-title":"Vasa"},{"key":"4896_CR3","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00059-017-4638-2","volume":"42","author":"C Espinola-Klein","year":"2017","unstructured":"Espinola-Klein\u00a0C (2017) ESC guidelines on peripheral arterial disease: summary of the most important recommendations and innovations. Herz 42:721\u2013727","journal-title":"Herz"},{"key":"4896_CR4","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1093\/eurheartj\/ehp355","volume":"30","author":"MJ Alberts","year":"2009","unstructured":"Alberts\u00a0MJ, Bhatt\u00a0DL, Mas\u00a0JL et al (2009) Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry. Eur Heart\u00a0J 30:2318\u20132326","journal-title":"Eur Heart J"},{"key":"4896_CR5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S0021-9150(03)00204-1","volume":"172","author":"C Diehm","year":"2004","unstructured":"Diehm\u00a0C, Schuster\u00a0A, Allenberg\u00a0H et\u00a0al (2004) High prevalence of peripheral arterial disease and comorbidity in 6,880 primary care patients: cross sectional study. Atherosclerosis 172:95\u2013105","journal-title":"Atherosclerosis"},{"key":"4896_CR6","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/j.jvs.2006.12.037","volume":"45","author":"L Norgren","year":"2007","unstructured":"Norgren\u00a0L, Hiatt\u00a0WR, Dormandy\u00a0JA et al (2007) Inter-society consensus for the management of peripheral arterial disease (TASC II). J\u00a0Vasc Surg 45(Suppl):S5\u201367","journal-title":"J Vasc Surg"},{"key":"4896_CR7","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1093\/eurheartj\/ehv006","volume":"36","author":"H Reinecke","year":"2015","unstructured":"Reinecke\u00a0H, Unrath\u00a0M, Freisinger\u00a0E et\u00a0al (2015) Peripheral arterial disease and critical limb ischaemia: still poor outcomes and lack of guideline adherence. Eur Heart\u00a0J 36:932\u2013938","journal-title":"Eur Heart J"},{"issue":"eS109","key":"4896_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejvs.2019.05.006","volume":"58","author":"MS Conte","year":"2019","unstructured":"Conte\u00a0MS, Bradbury\u00a0AW, Kolh\u00a0P et al (2019) Global vascular guidelines on the management of chronic limb-threatening Ischemia. Eur J Vasc Endovasc Surg 58(eS109):1","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"4896_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz486","author":"F Cosentino","year":"2019","unstructured":"Cosentino\u00a0F, Grant\u00a0PJ, Aboyans\u00a0V et al (2019) ESC\/EASD Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. Eur Heart\u00a0J. https:\/\/doi.org\/10.1093\/eurheartj\/ehz486","journal-title":"Eur Heart J"},{"key":"4896_CR10","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1161\/CIRCULATIONAHA.107.763227","volume":"118","author":"C Espinola-Klein","year":"2008","unstructured":"Espinola-Klein\u00a0C, Rupprecht\u00a0HJ, Bickel\u00a0C et al (2008) Different calculations of ankle-brachial index and their impact on cardiovascular risk prediction. Circulation 118:961\u2013967","journal-title":"Circulation"},{"key":"4896_CR11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s00059-018-4774-3","volume":"44","author":"C Espinola-Klein","year":"2019","unstructured":"Espinola-Klein\u00a0C, Vosseler\u00a0M, Abegunewardene\u00a0N et al (2019) Peripheral arterial occlusive disease as predictor of high atherosclerotic burden. Herz 44:40\u201344","journal-title":"Herz"},{"key":"4896_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach\u00a0F, Baigent\u00a0C, Catapano\u00a0AL et\u00a0al (2020) 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart\u00a0J 41:111\u2013188","journal-title":"Eur Heart J"},{"key":"4896_CR13","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams\u00a0B, Mancia\u00a0G, Spiering\u00a0W et\u00a0al (2018) ESC\/ESH Guidelines for the management of arterial hypertension. Eur Heart\u00a0J 39:3021\u20133104","journal-title":"Eur Heart J"},{"key":"4896_CR14","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal\u00a0B, Perkovic\u00a0V, Mahaffrey\u00a0KW et\u00a0al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N\u00a0Engl J Med 377:644\u2013657","journal-title":"N Engl J Med"},{"key":"4896_CR15","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1161\/CIRCULATIONAHA.117.032031","volume":"137","author":"S Verma","year":"2018","unstructured":"Verma\u00a0S, Mazer\u00a0CD, Al-Omran\u00a0M et al (2018) Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes mellitus and peripheral artery disease: a subanalysis of EMPA-REG OUTCOME. Circulation 137:405\u2013407","journal-title":"Circulation"},{"key":"4896_CR16","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1055\/a-0639-8325","volume":"143","author":"K Kr\u00f6ger","year":"2018","unstructured":"Kr\u00f6ger\u00a0K, Espinola-Klein\u00a0C, Hoffmann\u00a0U et al (2018) Peripheral arterial disease: When is a\u00a0PCSK9 inhibitor useful? Dtsch Med Wochenschr 143:1391\u20131396","journal-title":"Dtsch Med Wochenschr"},{"key":"4896_CR17","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","volume":"137","author":"MP Bonaca","year":"2018","unstructured":"Bonaca\u00a0MP, Nault\u00a0P, Giugliano\u00a0RP et al (2018) Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial. Circulation 137:338\u2013350","journal-title":"Circulation"},{"key":"4896_CR18","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1161\/CIRCULATIONAHA.117.032361","volume":"137","author":"S Arya","year":"2018","unstructured":"Arya\u00a0S, Khakharia\u00a0A, Binney\u00a0ZO et\u00a0al (2018) Association of Statin dose with amputation and survival in patients with peripheral artery disease. Circulation 137:1435\u20131446","journal-title":"Circulation"},{"key":"4896_CR19","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","volume":"348","author":"CAPRIE Steering Committee","year":"1996","unstructured":"CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329\u20131339","journal-title":"Lancet"},{"key":"4896_CR20","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","volume":"391","author":"SS Anand","year":"2017","unstructured":"Anand\u00a0SS, Bosch\u00a0J, Eikelboom\u00a0JW et al (2017) Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 391:219\u2013229","journal-title":"Lancet"},{"key":"4896_CR21","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1007\/s00392-016-0966-0","volume":"105","author":"JF Dopheide","year":"2016","unstructured":"Dopheide\u00a0JF, Geissler\u00a0P, Rubrech\u00a0J et al (2016) Influence of exercise training on proangiogenic TIE\u20112 monocytes and endothelial progenitor cells in patients with peripheral arterial disease. Clin Res Cardiol 105:666\u2013676","journal-title":"Clin Res Cardiol"},{"key":"4896_CR22","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1177\/2047487316665231","volume":"24","author":"JF Dopheide","year":"2017","unstructured":"Dopheide\u00a0JF, Rubrech\u00a0J, Trumpp\u00a0A et\u00a0al (2017) Supervised exercise training in peripheral arterial disease increases vascular shear stress and profunda femoral artery diameter. Eur J Prev Cardiol 24:178\u2013191","journal-title":"Eur J Prev Cardiol"},{"key":"4896_CR23","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1177\/2047487319846999","volume":"26","author":"M Venermo","year":"2019","unstructured":"Venermo\u00a0M, Sprynger\u00a0M, Desormais\u00a0I et al (2019) Follow-up of patients after revascularisation for peripheral arterial diseases: a\u00a0consensus document from the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases and the European Society for Vascular Surgery. Eur J Prev Cardiol 26:1971\u20131984","journal-title":"Eur J Prev Cardiol"},{"key":"4896_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/JAHA.113.000697","volume":"3","author":"EJ Armstrong","year":"2014","unstructured":"Armstrong\u00a0EJ, Chen\u00a0DC, Westin\u00a0GG et al (2014) Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease. J\u00a0Am Heart Assoc 3:1\u201311","journal-title":"J Am Heart Assoc"}],"container-title":["Herz"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-020-04896-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00059-020-04896-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-020-04896-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T01:20:05Z","timestamp":1614907205000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00059-020-04896-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,5]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["4896"],"URL":"https:\/\/doi.org\/10.1007\/s00059-020-04896-1","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,5]]},"assertion":[{"value":"5 March 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>C.\u00a0Espinola-Klein<\/b> gibt folgende Interessenkonflikte an: Vortrags- und\/oder Beratungst\u00e4tigkeit f\u00fcr Amgen GmbH, Bayer Health Care, Berlin-Chemie Menarini, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer Pharma GmbH, Daiichi Sankyo, Leo Pharma, MSD Sharp & Dohme, Sanofi Aventis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf ExternalRef removed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}